Trikona Pharmaceuticals

Trikona Pharmaceuticals is a specialty pharmaceutical company focused on the development of advanced drug delivery systems, primarily utilizing nanotechnology to improve the therapeutic index of oncology medications. The company's proprietary platform specializes in the solubilization of Biopharmaceutics Classification System (BCS) Class II and IV drugs, which are typically difficult to formulate due to poor water solubility. Trikona's lead programs involve micellar and nanoparticle formulations of potent chemotherapeutic agents like paclitaxel and docetaxel. In 2016, the company was acquired by Shilpa Medicare, integrating its innovative delivery technologies into Shilpa's broader oncology portfolio. Trikona continues to operate as a research-driven entity dedicated to creating differentiated pharmaceutical products with enhanced clinical outcomes.